TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DAKLINZA

DACLATASVIR DIHYDROCHLORIDE
Approved 2015-07-24
2
Indications
--
Phase 3 Trials
2
Priority Reviews
10
Years on Market

Details

Status
Discontinued
First Approved
2015-07-24
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: DACLATASVIR DIHYDROCHLORIDE

DAKLINZA Approval History

Loading approval history...

What DAKLINZA Treats

2 FDA approvals

Originally approved for its first indication in 2015 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DAKLINZA FDA Label Details

Pro

DAKLINZA Patents & Exclusivity

Latest Patent: Jun 2031

Patents (54 active)

US8629171 Expires Jun 13, 2031
US8329159 Expires Jul 24, 2029
US8642025 Expires Aug 11, 2027
US8900566 Expires Aug 8, 2027
US9421192 Expires Aug 8, 2027
+ 44 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.